

Progress Report of the activities of the Working Group
« Hypertension and the Kidney » 2017-2018

Contents

Members 2
WG meetings 2
Fibromuscular Dysplasia (FMD)..... 5
Hypertension in dialysis 6
Hypertension in renal transplantation 6
Publications on behalf of the WG 7

Members

The updated list of members of the WG with their areas of interest is available on the ESH website:

<http://www.eshonline.org/esh-content/uploads/2018/05/WG-on-Hypertension-and-the-Kidney-1.pdf>

The WG is composed of 41 members from 16 countries.

The map shows the countries currently represented in the WG (except for Argentina and Japan).



The board is composed of the Chair (Prof. Alexandre Persu, Belgium), the past Chair (Prof. Peter de Leeuw, The Netherlands), the Secretary (Dr Gregor Wuerzner, Switzerland) and an officer in charge of relations with ERA/EDTA (Prof. Patrick Rossignol, France). The statutes, approved in May 2016, are available on the website.

Election of the new President and the new Secretary is planned for 2019.

WG meetings

The Chair and the Secretary have regular telephone conferences to organize and to follow progress of the objectives of the WG.

Newsletters are sent to the members on a regular basis to inform them about the activities and meetings proposed by the WG.

The next meeting of the Board is scheduled on Saturday 9th June at the annual ESH meeting in Barcelona.

The activities organized by the WG for this meeting are listed below:

ESH 2018: Hands-on workshop and business meetings

HANDS-ON RENAL ULTRASOUND IN HYPERTENSION (BASICS)

Friday, 8th June, 13.00-17.00, Room B2

Chairpersons: A. Persu (Brussels, BELGIUM), G. Wuerzner (Lausanne, SWITZERLAND)

13:00 - 13:10	Welcome address A. Persu (Brussels, BELGIUM) G. WUERZNER (LAUSANNE, SWITZERLAND)
13:10 - 13:40	Technical basics of ultrasound and indications to perform a renal ultrasound in hypertensive patients M. Pruijm (Lausanne, SWITZERLAND)
13:25 - 13:40	Normal anatomic findings and normal variants U. Eisenberger (Essen, GERMANY)
13:40 - 13:55	Common abnormalities of the renal and urogenital tract (renal masses, nephrolithiasis, hydronephrosis) M. Rivera Gorrin (Alcalá, SPAIN)
13:55 - 14:30	How to screen for renal artery stenosis: atherosclerotic stenosis and fibromuscular dysplasia A. Persu (Brussels, BELGIUM), B. Ponte (Veyrier, SWITZERLAND)
14:30 - 15:10	Demonstration of kidney ultrasound basics by experts M. Cintra (Madrid, SPAIN), B. Ponte (Veyrier, SWITZERLAND) M. Pruijm (Lausanne, SWITZERLAND) M. Rivera Gorrin (Alcalá, SPAIN)
15:10 - 16:50	Hands-on kidney ultrasound with healthy volunteers (supervision by experts) M. Cintra (Madrid, SPAIN), B. Ponte (Veyrier, SWITZERLAND) M. Pruijm (Lausanne, SWITZERLAND) M. Rivera Gorrin (Alcalá, SPAIN)
16:50 - 17:00	General Discussion

ESH 2018 BUSINESS MEETING

Saturday, 9th June, 18.15-19.45, room C2

Chairs: A. Persu (Brussels, Belgium), G. Wuerzner (Lausanne, Switzerland)

Agenda:

- New members
- European Fibromuscular Dysplasia Initiative
- Survey on BP measurement in dialysis
- Systematic review on HTN in renal transplantation
- Composition of the Board
- Free proposals; varia

Presentations supported by the WG at the ESH2018:

Sunday, June 10 07:45 - 08:45

ROOM C1 FIBROMUSCULAR DYSPLASIA

07:45 - 08:05

Revisiting Fibromuscular Dysplasia: Rationale and first achievements of the European Fibromuscular Dysplasia Initiative. A. Persu (Brussels, BELGIUM)

08:05 - 08:25

The genetics of Fibromuscular dysplasia. X. Jeunemaitre (Paris, FRANCE)

08:25 - 08:45

Discussion

Sunday, June 10 10:30 - 11:00

ROOM A1

Lecture

FIRST INTERNATIONAL CONSENSUS ON FIBROMUSCULAR DYSPLASIA. A. Persu (Brussels, BELGIUM)

Sunday, June 10 18:15-19.45

ROOM 7 KIDNEY AND RAAS

Poster

Poor adherence to blood pressure measurement recommendations in European dialysis centers. G.Wuerzner et al. (Switzerland)

Monday, June 11 12:45 - 14:15

ROOM B2 SESSION 3

12:45 - 12:55

ESH-ENDORSED EUROPEAN/INTERNATIONAL FIBROMUSCULAR DYSPLASIA REGISTRY: RESULTS OF THE FIRST 609 PATIENTS. A.Persu et al . (Brussels. Belgium).

Fibromuscular Dysplasia (FMD)

The main objectives of the European FMD initiative are to (i) standardize clinical practice and update the European FMD consensus; (ii) establish a network of expert centers; (iii) establish a European patient association; (iv); establish a European registry; (v) dissect the genetics of FMD (GWAS/WES); (vi) coordinate research on FMD in Europe.

Symposium

International symposium “Revisiting Fibromuscular Dysplasia and Related Vascular Diseases”. 22nd-24th February 2018, Belgian royal academy of Medicine, Brussels (Belgium). Endorsed by the ESH and supported by the Menarini Foundation (<http://www.en.fondazione-menarini.it/Home/News/Revisiting-Fibromuscular-Dysplasia-and-Related-Vascular-Diseases/Postcards>). Chairmen: Prof. Heather Gornik (Cleveland) and Alexandre Persu (Brussels). The symposium was followed by a patients’ meeting at the “Fondation Universitaire”.



This International Symposium has provided a unique state-of-the art on FMD, Spontaneous Coronary Artery Dissection (SCAD) and related arterial diseases, with participation of a bunch of top experts from Europe, the USA and other parts of the world.

It has been instrumental to strengthen the links between experts from both sides of the Atlantic, to further harmonize the European and US FMD initiatives and to pave the way for the next generation of investigators.

European FMD Registry

The registry includes over 50 items covering demographic and clinical characteristics of FMD.

A flexible, user-friendly online version has been developed (L. Toubiana, Paris), allowing to add an indefinite number of new events/visits.

A new expanded version is in preparation and should be released before end 2018.

The registry is linked with a wide scale genetic project (Prof. N. Bouatia-Naji and X. Jeunemaitre, Paris).

As of now, 15 European countries have included over 800 patients, which corresponds to a doubling of the inclusions since last year.

The registry is becoming more and more international, with inclusion of Argentina, China, Japan and Tunisia.

The results obtained in the first 609 patients will be presented at the Barcelona meeting (see program above).

The WG is actively searching to recruit new centers, particularly in Northern and Central-Eastern Europe, which are currently less represented.

An official call for participation with contact data is available on the ESH website:

<http://www.eshonline.org/esh-content/uploads/2016/10/Call-FMD-registry-2016.pdf>.

The support of the “Excellence centers” network to raise awareness about FMD and stimulate participation to the registry remains of critical importance.

An international consensus on the management of FMD coordinated by Prof. A. Persu (Brussels) and H. Gornik (Cleveland) on behalf of the ESH WG “Hypertension and the Kidney” and the Society for Vascular Medicine (SVM) is under revision. Online publication is expected early in Autumn 2018.

A summary of the consensus will be presented at the ESH meeting in Barcelona (see above).

Hypertension in dialysis

The WG has initiated a strong collaboration with the European Renal and Cardiovascular Medicine (EURECA-m) WG of the ERA/EDTA (Current Chair.: Prof. F. Mallamaci).

An online survey on the adequacy of blood pressure measurements in dialysis centers across Europe has been completed end May 2017. Ninety-seven physicians working in dialysis centers from 36 countries have participated to the survey. Half of the centers originated from seven countries. The overall results have been presented as an oral presentation in December 2017 at the French Society of Hypertension and will be presented as a poster at the 2018 ESH meeting in Barcelona.

A similar survey with a focus on patients has been conducted in dialysis centers. 210 patients responded to the survey, along with responses from 14 physicians and 13 nurses. Results from this survey should be available by the end of the year 2018 and should be presented at the annual meeting of the ESH 2019.

Hypertension in renal transplantation

As was previously done for hypertension in dialysis (Sarafidis et al., J Hypertens. 2017 Apr;35(4):657-676/ Nephrol Dial Transplant. 2017 Apr 1;32(4):620-640.), a collaboration with Prof. J.-M. Halimi (WG “Hypertension and the Kidney”) and Prof. C. Zoccali (ERA-EDTA, EURECA-m) has been initiated in order to reach a consensus on the optimal management of hypertension in patients with renal transplantation.

As a first step, a call-to-action has been co-published in the *Journal of Hypertension* and in *Nephrology, Dialysis and Transplantation* (Halimi et al., *J Hypertens.* 2017 Dec;35(12):2335-2338; *Nephrol Dial Transplant.* 2017 Dec 1;32(12):1959-1962).

A comprehensive meta-analysis on the effect of antihypertensive drugs on patient and graft survival and other kidney endpoints in renal transplantation is being completed, and the corresponding manuscript is in preparation.

The latter will pave the way for a wider consensus involving both working groups.

Publications on behalf of the WG

Wuerzner G, Krieger C, Bouchardy J, Toubiana L, Delmotte P, Van der Niepen P, Deglise S, Qanadli S, Burnier M, Mazzolai L, Persu A: [Fibromuscular dysplasia and hypertension : beyond renal arteries]. *Rev Med Suisse* 2017;13:1580-1583.

Halimi JM, Persu A, Sarafidis PA, Burnier M, Abramowicz D, Sautenet B, Oberbauer R, Mallamaci F, London G, Rossignol P, Wuerzner G, Watschinger B, Zoccali C, European Renal, Cardiovascular Medicine (EURECA-m), the transplant DESCARTES working group of the European Renal Association-European Dialysis, Transplant Association (ERA-EDTA), the Working Group 'Hypertension, Kidney' of the European Society of Hypertension (ESH); the EKITA committee of the European Society of Organ Transplantation (ESOT), FCRIN INI-CRCT Cardiovascular, Renal Clinical Trialists. Optimizing hypertension management in renal transplantation: a call to action. *J Hypertens* 2017;35:2335-2338. *Nephrol Dial Transplant* 2017;32:1959-1962.

FIRST INTERNATIONAL CONSENSUS ON THE DIAGNOSIS AND MANAGEMENT OF FIBROMUSCULAR DYSPLASIA. Heather GORNIK (Co-Chair) *, Alexandre PERSU (Co-Chair) *, et al., on behalf of the Working Group "Hypertension and the Kidney" of the European Society of Hypertension (ESH) and the Society for Vascular Medicine (SVM). Submitted.